{"entity":{"id":"azd8421","kind":"drug","name":"AZD8421","aka":[],"tldr":"AZD8421 is a small-molecule inhibitor from AstraZeneca, in registered phase 2 trials for ovarian cancer.","summary":"AZD8421 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by AstraZeneca, in ovarian cancer. Described in the registry record as a cdk2 inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of AZD8421","url":"https://clinicaltrials.gov/search?intr=AZD8421"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06188520"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"AZD8421","modality":"Small-molecule inhibitor","mechanism":"Described in the registry record as a cdk2 inhibitor; the trial entries below carry the sponsor's wording.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/azd8421/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"trial":[{"id":"nct06188520","kind":"trial","name":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With ","route":"/trials/nct06188520/"}]}}